Abstract：
Human T-cell leukaemia virus type 1 (HTLV-1), an STI, is reported to be highly prevalent in Indigenous communities in Central Australia. HTLV-1 is an incurable, chronic infection which can cause Adult T-cell leukaemia/lymphoma (ATL). ATL is associated with high morbidity and mortality, with limited treatment options. We studied the prevalence of HTLV-1 and ATL in the state of Queensland, Australia.
Serum samples stored at healthcare services in Brisbane, Townsville and Cairns and at haemodialysis units in Brisbane (2018-2019) were screened for HTLV-1/2 antibodies using the Abbott ARCHITECT chemiluminescent microparticle immunoassay (CMIA) for antibodies against gp46-I, gp46-II and GD21 (Abbott CMIA, ARCHITECT). Reactive samples were confirmed through Western blot. Pooled Australian National Cancer Registry surveillance data reporting on cases coded for ATL (2004-2015) were analysed.
Two out of 2000 hospital and health services samples were confirmed HTLV-1-positive (0.1%, 95% CI 0.02% to 0.4%), both in older women, one Indigenous and one non-Indigenous. All 540 haemodialysis samples tested negative for HTLV. All samples were HTLV-2-negative. Ten out of 42 (24.8%) reported cases of ATL in Australia were from Queensland (crude incidence rate 0.025/100 000; 95% CI 0.011 to 0.045); most cases were seen in adult men of non-Indigenous origin. Nineteen deaths due to ATL were recorded in Australia.
We confirm that HTLV-1 and ATL were detected in Queensland in Indigenous and non-Indigenous people. These results highlight the need for HTLV-1 prevalence studies in populations at risk of STIs to allow the implementation of focused public health sexual and mother-to-child transmission prevention strategies.
Serum samples stored at healthcare services in Brisbane, Townsville and Cairns and at haemodialysis units in Brisbane (2018-2019) were screened for HTLV-1/2 antibodies using the Abbott ARCHITECT chemiluminescent microparticle immunoassay (CMIA) for antibodies against gp46-I, gp46-II and GD21 (Abbott CMIA, ARCHITECT). Reactive samples were confirmed through Western blot. Pooled Australian National Cancer Registry surveillance data reporting on cases coded for ATL (2004-2015) were analysed.
Two out of 2000 hospital and health services samples were confirmed HTLV-1-positive (0.1%, 95% CI 0.02% to 0.4%), both in older women, one Indigenous and one non-Indigenous. All 540 haemodialysis samples tested negative for HTLV. All samples were HTLV-2-negative. Ten out of 42 (24.8%) reported cases of ATL in Australia were from Queensland (crude incidence rate 0.025/100 000; 95% CI 0.011 to 0.045); most cases were seen in adult men of non-Indigenous origin. Nineteen deaths due to ATL were recorded in Australia.
We confirm that HTLV-1 and ATL were detected in Queensland in Indigenous and non-Indigenous people. These results highlight the need for HTLV-1 prevalence studies in populations at risk of STIs to allow the implementation of focused public health sexual and mother-to-child transmission prevention strategies.
摘要：
目的：人T细胞白血病病毒1型（HTLV-1），STI,据报道，在澳大利亚中部的土著社区中非常普遍。HTLV-1是无法治愈的，可引起成人T细胞白血病/淋巴瘤（ATL）的慢性感染。ATL与高发病率和死亡率相关，有限的治疗选择。我们研究了昆士兰州的HTLV-1和ATL的患病率，澳大利亚。
方法：布里斯班医疗服务机构储存的血清样本，汤斯维尔和凯恩斯以及布里斯班（2018-2019年）的血液透析单位使用雅培ARCHITECT化学发光微粒免疫测定法（CMIA）筛选了HTLV-1/2抗体，gp46-II和GD21(雅培CMIA，建筑师)。通过Western印迹确认反应性样品。收集的澳大利亚国家癌症登记监测数据报告编码为ATL（2004-2015）的病例进行了分析。
结果：2000个医院和卫生服务样本中有两个被证实为HTLV-1阳性（0.1％，95%CI0.02%至0.4%)，无论是在老年妇女，一个土著和一个非土著。所有540个血液透析样品的HTLV测试均为阴性。所有样品均为HTLV-2阴性。在澳大利亚报告的42例ATL病例中，有10例（24.8％）来自昆士兰州（粗发病率0.025/100000；95％CI0.011至0.045）；大多数病例发生在非土著血统的成年男性中。澳大利亚记录了因ATL造成的19例死亡。
结论：我们确认在昆士兰州原住民和非原住民中检测到HTLV-1和ATL。这些结果强调了在有性传播感染风险的人群中进行HTLV-1患病率研究的必要性，以允许实施有重点的公共卫生性和母婴传播预防策略。
方法：布里斯班医疗服务机构储存的血清样本，汤斯维尔和凯恩斯以及布里斯班（2018-2019年）的血液透析单位使用雅培ARCHITECT化学发光微粒免疫测定法（CMIA）筛选了HTLV-1/2抗体，gp46-II和GD21(雅培CMIA，建筑师)。通过Western印迹确认反应性样品。收集的澳大利亚国家癌症登记监测数据报告编码为ATL（2004-2015）的病例进行了分析。
结果：2000个医院和卫生服务样本中有两个被证实为HTLV-1阳性（0.1％，95%CI0.02%至0.4%)，无论是在老年妇女，一个土著和一个非土著。所有540个血液透析样品的HTLV测试均为阴性。所有样品均为HTLV-2阴性。在澳大利亚报告的42例ATL病例中，有10例（24.8％）来自昆士兰州（粗发病率0.025/100000；95％CI0.011至0.045）；大多数病例发生在非土著血统的成年男性中。澳大利亚记录了因ATL造成的19例死亡。
结论：我们确认在昆士兰州原住民和非原住民中检测到HTLV-1和ATL。这些结果强调了在有性传播感染风险的人群中进行HTLV-1患病率研究的必要性，以允许实施有重点的公共卫生性和母婴传播预防策略。
